| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/14/2005 | US20050154202 Substituted aryl amides |
| 07/14/2005 | US20050154190 compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc. |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154062 Substituted chiral allosteric hemoglobin modifiers |
| 07/14/2005 | US20050154045 E.g., N-[4-(2-Thienyl)phenyl]-1-azabicyclo[2.2.2]octane-3-carboxamide hydrochloride; treatment of impairments of perception, concentration, learning and/or memory |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154028 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-2-one; serotonin 5-ht2c receptor antagonist; antidepressant and anxiolytic agent |
| 07/14/2005 | US20050154026 Suitable for the treatment of gastric and intestinal disorders; in particular, omeprazole, rabeprazole, pantoprazole, esomeprazole |
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050154023 1-(4-methoxynaphthalene-1-sulfonyl)-2,3-dihydro-1H-indole-3-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]amide; selective affinity for 5-HT6 receptor; psychosis, schizophrenia, depression, neurological disorders, cognitive enhancement, Parkinson's disease, ALS, Alzheimer's, Huntington's disease |
| 07/14/2005 | US20050154021 N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith |
| 07/14/2005 | US20050154018 Method for treating and preventing disorders using optically pure (+) norcisapride |
| 07/14/2005 | US20050154008 Aryl fused substituted 4-oxy-pyridines |
| 07/14/2005 | US20050154005 Administering to a subject in need of such treatment an effective amount of 1,1'-[1,4-(phenylenebis(methylene))]bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutical composition thereof, wherein the inhibition of CXCR4 receptor binding effects treatment or amelioration of said condition |
| 07/14/2005 | US20050153997 Fredericamycin derivatives |
| 07/14/2005 | US20050153993 Treatment of statin side effects using uridine derivatives |
| 07/14/2005 | US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates |
| 07/14/2005 | US20050153988 Novel polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| 07/14/2005 | US20050153987 Compounds |
| 07/14/2005 | US20050153986 Psychiatric and mood disorders, Bipolar Disorder, Circadian rhythm disorders, sleep disorders, pain, Parkinson's disease, cognitive dysfunction, epilepsy, obesity, drug addiction, drug abuse, drug withdrawal; side effects reduction; 1-Methyl-3-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]imidazolidin-2-one |
| 07/14/2005 | US20050153983 Synergistic combination of an opioid analgesic and a nsaid |
| 07/14/2005 | US20050153981 N1-phenacyl-N4-[2-(benzylamino)-2-oxo-ethyl] piperazine; as neuroprotective agents, in the treatment of ischemic cerebral apoplexy, human cerebral infraction; antiischemic agents for brain disorders; side effect reduction |
| 07/14/2005 | US20050153980 Substituted indoles |
| 07/14/2005 | US20050153978 Medicaments |
| 07/14/2005 | US20050153974 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153967 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 07/14/2005 | US20050153963 exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153957 Beta2-adrenoceptor agonists |
| 07/14/2005 | US20050153941 Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
| 07/14/2005 | US20050153930 Via gadolinium compounds as calcium channel blockers; drug screening |
| 07/14/2005 | US20050153928 Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
| 07/14/2005 | US20050153912 Antiviral oligonucleotides targeting viral families |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153889 Modulation of pericyte proliferation |
| 07/14/2005 | US20050153888 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/14/2005 | US20050153886 nucleotide sequences comprising cDNA and genomic DNA that code for angiogenesis factors, used for gene therapy |
| 07/14/2005 | US20050153871 Administering N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016) to increase or prevent a decrease in cerebral blood flow |
| 07/14/2005 | US20050153372 Using calmodulin-dependent protein kinase and/or calcineurin as tool in detecting modulators of nervous system and brain disorders; enzyme inhibitors |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050152985 The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system. |
| 07/14/2005 | US20050152959 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
| 07/14/2005 | US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis |
| 07/14/2005 | US20050152925 Method for treating pain by peripheral administration of a neurotoxin |
| 07/14/2005 | US20050152924 Methods for treating sinus headache |
| 07/14/2005 | US20050152878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 07/14/2005 | US20050150489 Dispensing medicaments based on rates of medicament action |
| 07/14/2005 | US20050150488 Dose dispensing system and apparatus |
| 07/14/2005 | DE10360151A1 New 3-oxo-1-propenyl azo compounds useful as 5-HT receptor antagonists e.g. for treating psychoses, neurological disorders, amyotrophic lateral sclerosis and eating disorders |
| 07/14/2005 | CA2551637A1 Melatonin combination therapy for improving sleep quality |
| 07/14/2005 | CA2551611A1 Thiazole derivatives for treating or preventing parkinson's disease |
| 07/14/2005 | CA2550735A1 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 07/14/2005 | CA2550689A1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| 07/14/2005 | CA2550435A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 07/14/2005 | CA2550383A1 Methods and compositions for directing migration of neural progenitor cells |
| 07/14/2005 | CA2550375A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 07/14/2005 | CA2549638A1 Therapeutic combination for cognition enhancement and psychotic disorders |
| 07/14/2005 | CA2548318A1 Benzo-1, 4 diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof |
| 07/14/2005 | CA2547645A1 Use of rotigotine for the treatment or prevention of dopaminergic neuron loss |
| 07/14/2005 | CA2546797A1 Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease |
| 07/14/2005 | CA2546147A1 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 07/14/2005 | CA2545324A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553092A1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 07/13/2005 | EP1553089A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1553084A1 Piperidine derivative, process for producing the same, and use |
| 07/13/2005 | EP1553083A1 Prostaglandin derivatives |
| 07/13/2005 | EP1552857A1 Apparatus for dispensing medicaments |
| 07/13/2005 | EP1552847A1 Inhibitors for continuous activation of calcineurin |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552836A1 Anti-neurodegenerative agents |
| 07/13/2005 | EP1552834A1 Neurotrophic factor production promoter |
| 07/13/2005 | EP1552826A1 Amino acid compositions for improving central functions |
| 07/13/2005 | EP1552822A1 Patch |
| 07/13/2005 | EP1551992A2 Screening molecules with anti-prion activity: kits, methods and screened molecules |
| 07/13/2005 | EP1551972A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 07/13/2005 | EP1551872A2 G-protein coupled receptors |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551846A1 Azabicyclic spiroether derivatives as receptor antagonists |
| 07/13/2005 | EP1551843A1 Diazabicyclic compounds useful in the treatment of cns and other disorders |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551840A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551836A1 Azabicyclic amine derivatives as nk-1 receptor antagonists |
| 07/13/2005 | EP1551835A1 Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| 07/13/2005 | EP1551834A1 Substituted quinazolinone compounds |
| 07/13/2005 | EP1551821A1 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia |
| 07/13/2005 | EP1551815A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 07/13/2005 | EP1551809A1 Pyrazole compounds for treatment of neurodegenerative disorders |
| 07/13/2005 | EP1551808A1 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ b,f AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
| 07/13/2005 | EP1551799A1 Cyclohexyl sulphones as gamma-secretase inhibitors |
| 07/13/2005 | EP1551798A1 Novel sulphones for inhibition of gamma secretase |
| 07/13/2005 | EP1551793A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 07/13/2005 | EP1551791A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 07/13/2005 | EP1551763A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |